Clinical data | |
---|---|
Other names | BAY 86-5310; SH-T04211C; ZK283197 |
Routes of administration | By mouth |
Drug class | Estrogen; Selective ERβ agonist |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number |
|
PubChem CID | |
PubChem SID | |
UNII | |
Chemical and physical data | |
Formula | C20H25FO2 |
Molar mass | 316.416 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
|
ZK-283197 (also known as BAY 86-5310 or SH-T04211C) is a selective and orally active ERβ agonist which was under development by Bayer Healthcare AG for the treatment of vasomotor symptoms. It reached phase II clinical trials prior to the discontinuation of its development. Its development was terminated in 2014.
References
- ^ "ZK 283197". AdisInsight. Springer Nature Switzerland AG.
- US 332204, Pietras RJ, Jung ME, "Methods of using estrogen receptor-beta ligands as radiation mitigators", published 2015-01-15
This drug article relating to the genito-urinary system is a stub. You can help Misplaced Pages by expanding it. |
This drug article relating to the nervous system is a stub. You can help Misplaced Pages by expanding it. |